Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupThoracic TumorsDiseasePleural MesotheliomaSubgroupICD10C45.0MeSHMesotheliomaSequencePEMB200/PEME500/CISP75, Pleural Mesothelioma (PID2597) -|- PEMB200, Erh. (PID2613)PEMB200/PEME500/CRBP5, Pleural Mesothelioma (PID2598) -|- PEMB200, Erh. (PID2613)ChemotherapyChemo-substanceBevacizumabCarboplatinCisplatinEpirubicinGemcitabineIpilimumabNivolumabPembrolizumabPemetrexedRamucirumabVinorelbineChemo-substanceBevacizumabCarboplatinCisplatinEpirubicinGemcitabineIpilimumabNivolumabPembrolizumabPemetrexedRamucirumabVinorelbineChemo-substanceBevacizumabCarboplatinCisplatinEpirubicinGemcitabineIpilimumabNivolumabPembrolizumabPemetrexedRamucirumabVinorelbineChemo-substanceBevacizumabCarboplatinCisplatinEpirubicinGemcitabineIpilimumabNivolumabPembrolizumabPemetrexedRamucirumabVinorelbineNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances1234679Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaBleedingCardiotoxicityColitisConstipationDehydrationDiarrheaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHepatotoxicityHyperbilirubinemiaHypertensionHyperthyroidismHypothyroidismIncrease AminotransferasesMucositisNauseaNeuropathyNeutropeniaOral MucositisPancreatitisPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAlley EWBaas PChu QHaarst JMWJassem JMattson K Muers MFNowak AKPinto CSantoro AScherpereel AStebbing JToyokawa GVogelzang NJZalcman GDiseaseErstlinientherapie beim inoperablen, malignen Pleuramesotheliom, Karnofsky Status > 70Erstlinientherapie beim malignen Pleuramesotheliom, Alter <75 Jahre, ECOG 0-2Erstlinientherapie beim malignen Pleuramesotheliom, ECOG 0-2fortgeschrittenes Pleuramesotheliom, Erstlinie, ECOG 0-1inoperables, malignes Pleuramesotheliom, Erst- oder Zweitlinie, Karnofsky Status >70Lokal fortgeschrittenes oder metastasierten Pleuramesotheliom, vortherapiert oder chemotherapieungeeignet, PD-L1 positiv, ECOG 0-1Malignes Pleuramesotheliomnicht resezierbares Pleuramesotheliom ohne vaskuläre Komorbidität, Erstlinie, ECOG 0-2Pleuramesotheliom, Erstlinie, ECOG 0-1Pleuramesotheliom, metastasiert, nach platinhaltiger Chemotherapie, ECOG 0-1Pleuramesotheliom, Progress nach Platin/Pemetrexed, ECOG 0-2Pleuramesotheliom, unter 75 J, ECOG 0-2Pleuramesotheliom, Zweitlinie nach Platin-Pemetrexed, ECOG 0-1Zweitlinientherapie beim fortgeschrittenen, malignen Pleuramesotheliom, Karnofsky Status >70Zweitlinientherapie des malignen Pleuramesothelioms, ECOG 0-2OriginCross Cancer Institute, Edmonton, AB, Canada, IND227 TrialDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, AustraliaDepartment of Medical Oncology, St. Bartholomew's Hospital, LondonDepartment of Pulmonary and Thoracic Oncology, University of Lille, University Hospital of Lille, France, MAPS-2Department of Pulmonology and Thoracic Oncology, University of Caen, France, MAPSDepartment of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, JapanInstituto Clinico Humanitas, Rozzzano, ItalyMedical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Italy, RAMESMedical University of GdanskMRC Clinical Trials Unit, LondonPenn Presbyterian Medical Center, University of Pennsylvania Health System, Philadelphia, PA, USA, KEYNOTE-028Rotterdam Oncological Thoracic StudygroupThe Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, Netherlands, CheckMate 743 trialUniversity Central Hospital, Helsinki, FinlandUniversity of Chicago Cancer Research CenterProtocols in Revision 17 protocols foundProtocols under revision.Cisplatin 100 / Gemcitabine 1000, Pleural Mesothelioma (PID373 V1.1)Epirubicin 110, Pleural Mesothelioma (PID2567 V1.0)Gemcitabine 1000 / Vinorelbine 25, Pleural Mesothelioma (PID2566 V1.0)Gemcitabine 1250 / Cisplatin 80, Pleural Mesothelioma (PID374 V1.1)Nivolumab 3 / Ipilimumab 1, Pleural Mesothelioma (PID1203 V1.2)Nivolumab 360 / Ipilimumab 1, Pleural Mesothelioma, first-line (PID1919 V1.1)Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Pleural Mesothelioma (PID2598 V1.0)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Pleural Mesothelioma (PID2597 V1.0)Pembrolizumab 200, Pleural Mesothelioma (PID1636 V1.0)Pembrolizumab 200, Pleural Mesothelioma, maintenance (PID2613 V1.0)Pemetrexed 500 / Carboplatin 5, Pleural Mesothelioma (PID391 V1.0)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 15, Pleural Mesothelioma (PID830 V1.1)Pemetrexed 500 / Cisplatin 75, Pleural Mesothelioma (PID390 V1.1)Pemetrexed 500, Pleural Mesothelioma (PID392 V1.0)Ramucirumab 10 / Gemcitabine 1000, Pleural Mesothelioma (PID2155 V1.0)Vinorelbine 30, Pleural Mesothelioma (PID375 V1.0)Vinorelbine 30, Pleural Mesothelioma, Variant 1 (PID376 V1.1)
